Potentials of nivolumab in the treatment of refractory Hodgkin’s lymphoma: literature review and authors’ own observation


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Immunotherapy with a PD-1 inhibitor (nivolumab) is highly effective in relapses and refractory forms of classical Hodgkin’s lymphoma (HL). In some cases, the use of this drug is considered the only possible treatment option for these patients with extremely unfavorable prognosis. The article describes the clinical observation of a female patient with relapses and a refractory course of HL, who underwent initiation of an early access program on the use of nivoluumab after 10 years of treatment of classical LH with various chemotherapy regimens, radiation therapy, and surgical treatment without a significant clinical and objective response. The treatment consisted of 40 nivoluumab injections, after which complete remission was achieved.

全文:

受限制的访问

作者简介

Mariya Kichigina

N.N. Blokhin National Medical Research Center of Oncology

Email: kitchmar@mail.ru
MD, Oncologist, Department of Chemotherapy of Hemoblastosis, Division of Hematology and Bone Marrow Transplantation

E. Demina

National Medical and Surgical Center N.I. Pirogov

Department of Hematology and Cell Therapy, Institute of Advanced Medical Studies

G. Tumyan

N.N. Blokhin National Medical Research Center of Oncology

E. Osmanov

Sechenov First Moscow State Medical University (Sechenov University)

P. Zeynalova

N.N. Blokhin National Medical Research Center of Oncology

参考

  1. Hodgkin T. On some morbid experiences of the absorbent glands and spleen. Med. Chir. Trans. 1832;17:69-97
  2. Weiss L.M., Chan J.K.C., MacLennan K., Warnke R.A. Pathology of classical Hodgkin's disease. In: P.M. Mauch, J.O. Armitage, V. Diehl, R.T Hoppe, L.M. Weiss, (eds). Hodgkin's disease. USA: Lippencott Williams & Wilkins. Philadelphia. Pennsylvania. 1999:101-20.
  3. Kanzler H., Kuppers R., Hansmann M.L., Rajewsky K. Hodgkin and Reed-Sternberg cell in Hodgkin's disease represent the outgrowth of a dominant tumor clone deriver from (crippled) germinal center B. cell. J. Exp. Med. 1996;184:1495-505.
  4. Kuppers R., Rajewsky K. The origin of Hodgkin and Reed- Sternberg cell in Hodgkin's disease. Ann. Rev. Immunol. 1998;16:471-93.
  5. Weber-Matthiesen K., Deerberg J.U., Poetsch M., et. al. Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cell in 100% of analyzed cases of Hodgkin's disease. Blood. 1995;86: 1464-68.
  6. Green M.R., Monti S., Rodig S.J., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268-77. doi: 10.1182/blood-2010-05-282780.
  7. Rui L., Emre N.C., Kruhlak M.J., et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18:590-605. Doi: 10.1016/j. ccr.2010.11.013.
  8. Wang C., Thudium K.B., Han M., et al. In vitro characterization of the anti-PD-1 antibody nivolumab, bms-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2014;2:846-56. doi: 10.1158/2326-6066.CIR- 14-0040.
  9. Carey C.D., Gusenleitner D., Lipschitz M., et al. Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130(22):2420-30. doi: 10.1182/blood-2017-03-770719.
  10. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 2012;12: 252-64. doi: 10.1038/nrc3239.
  11. Ribas A. Releasing the Brakes on Cancer immunotherapy. N. Engl. J. Med. 2015;373:1490 2. doi: 10.1056/NEJMp1510079
  12. Инструкция по медицинскому применению препарата ОПДИВО® от30.07.2018

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2018
##common.cookie##